Maruha Nichiro Announces Strategic Investment and Development Collaboration with Umami Bioworks on the Development of Cultivated Seafood in Japan

The Japanese fishing giant will access Umami Bioworks’ cell cultivation development and manufacturing platform as part of a collaboration to develop and commercialize cultivated seafood production in Japan and beyond

Umami Bioworks (formerly known as Umami Meats), a Singapore-headquartered company developing the development and manufacturing system for producing cultivated seafood, announced their official collaboration with Japan’s largest fishing company, Maruha Nichiro (TYO: 1333). This is the first time a Japanese seafood company has chosen to invest in and collaborate with a foreign cell-cultivated seafood company.
Background:
While the demand for seafood has been growing worldwide, supply shortages are becoming a huge risk due to factors like overfishing and marine pollution. These challenges have led to decreasing wild-catch volumes, as well as health concerns around microplastics and heavy chemicals in seafood. In particular, Japan’s self-sufficiency rate for seafood remains at a low level of 55%, while the domestic wild-catch volumes have decreased approximately 65% over the last 30 years. This poses great risks not only to consumers, but also to the Japanese seafood industry, fishermen, and the overall economy.
Under such circumstances, cultivated products have attracted worldwide attention, with global investment in cultivated products reaching $2.8 billion in 2022. However, many Japanese companies are still lagging behind in participating actively in this industry. Maruha Nichiro has stepped up as a leader to ensure a sustainable supply of seafood worldwide, and to make its first formal investment in cellular agriculture with the aim of laying the foundation for Japan’s cell-cultivated seafood industry.
Umami Bioworks and Maruha Nichiro will be working to build the infrastructure of Japan’s cultivated seafood industry together in this partnership. The strategic investment from Maruha Nichiro will help accelerate Umami’s development progress. The two companies will also carry out a multi-faceted collaboration to accelerate the path to cultivated seafood commercialization, particularly in novel ETP (endangered, threatened and protected) species that have global relevance.
With this investment, Umami Bioworks will be able to expedite their long-term plan of building a research and commercial team in Japan. In turn, Maruha Nichiro will have a third method of sustainable production, other than fishing and aquaculture, for increasingly scarce seafood species.
By establishing a production pipeline of cell-cultivated products for the Japanese market, both companies will develop a foundation for cell-cultivated in Japan and provide the market with a sustainable and stable supply of locally produced seafood.
Mihir Pershad, CEO of Umami Bioworks, “Our seminal partnership with Maruha Nichiro, a global leader in crafting beloved food products, is a pivotal step in achieving our mission of addressing the challenge of feeding a growing global population while minimizing environmental impact. We have the development and production technology, but we require experienced partners with global reach that can help us manufacture and deliver cultivated products to consumers. Through collaborations with industry leaders like Maruha Nichiro, we can leverage our technology expertise to support co-development of delicious, nutritious, and appealing consumer products that secure a healthier and more sustainable food future for the world.”

Hot this week

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.